Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexa-Vec followed by sorafenib versus sorafenib in advanced hepatocellular carcinoma
2014-001985-86Phase 3Terminated
- Sponsor
- SillaJen
- Start
- Mar 2016
- Modality
- Small Molecules, Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Pexa-Vec followed by sorafenib with Sorafenib (2 arms). Primary endpoint: Overall survival. Started Mar 2016; status: terminated.
02
Drugs
vaccinia granulocyte-macrophage colony-stimulating factor recombinant virussorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2014-001985-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001985-86.